 The French RD; tax credit initiative Crédit dImpôt Recherche, or CIR gives eligible research-based French companies, which are subject to corporate tax in France, the ability to claim tax relief of up to 30 on costs incurred in RD; activities. The 30 tax relief on RD; activities provides a significant non-dilutive funding source for our on-going research and clinical trial activities in France and Europe through our AzurRx SAS subsidiary, said James Sapirstein, the CEO of AzurRx. The Research Tax Credit CIR is a tax incentive provided by the French Government to encourage the growth of businesses competitiveness by favoring research and development RD; and innovative activities. 